3
ALL1
Hämophilie-Zentrum Rhein Main2
OctapharmaYear
3
ALL3
2021DEALS // DEV.
3
ALL3
DevelopmentsCountry
3
ALL1
GERMANY2
SWITZERLAND3
ALL2
Not Applicable1
OctapharmaTherapeutic Area
3
ALL3
Genetic DiseaseStudy Phase
3
ALL3
ApprovedDeal Type
0
ALLProduct Type
3
ALL2
Large molecule1
PeptideDosage Form
3
ALL3
Intravenous InjectionLead Product
3
ALL3
Simoctocog AlfaTarget
3
ALL3
Factor VIIILead Product(s) : Simoctocog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NUWIQ is a recombinant antihemophilic factor [coagulation factor VIII] indicated in adults and children with Hemophilia A for treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequenc...
Brand Name : Nuwiq
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 05, 2021
Lead Product(s) : Simoctocog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Simoctocog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Octapharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MOTIVATE trial comprised regimens of human cell line-derived recombinant FVIII Nuwiq® or the plasma-derived FVIII products octanate® or wilate® for the management of patients with hemophilia A and inhibitors.
Brand Name : Nuwiq
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 28, 2021
Lead Product(s) : Simoctocog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Octapharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Simoctocog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The NuProtect study was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®.
Brand Name : Nuwiq
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 22, 2021
Lead Product(s) : Simoctocog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?